Save to Existing Project
Save to a New Project
Yeda R&D Co. Ltd
Abstract ID: 1441
Chronic lymphocytic leukaemia (CLL), a malignant disease characterized by the accumulation of B lymphocytes in the blood, lymphoid organs, and bone marrow, is the second most common type...
Chronic lymphocytic leukaemia (CLL), a malignant disease characterized by the accumulation of B lymphocytes in the blood, lymphoid organs, and bone marrow, is the second most common type of leukaemia in adults, accounting for about 7,000 new cases of leukaemia each year. Presently, there is no cure for CLL, and the overall goal of leukaemia treatment is to bring about a remission.
Therefore, identifying new proteins that may serve as a target for inducing cell death in the malignant cells is highly desirable.
The present technology identifies a new regulator protein that is essential for the survival of CLL cells. B cells taken from CLL patients have a high level of the protein CD84. Stimulation of CD84 upregulates the survival of B-CLL. However, inhibition of CD84 activity with a blocking antibody downregulates the expression of another protein which controls B-CLL survival, thus inducing cell death. Therefore, the present invention reveals CD84 as a regulator of B-CLL survival
We have elucidated a new protein as a target to treat B cell-related cancer.
Treatment of CLL, as well as other B cell-related cancers (eg, gastric cancer and renal cell carcinoma), by blocking CD84 activity. Please enquire regarding licensing or codevelopment partnerships quoting reference no. 1441.
Last Updated May 2015